AEB071

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

de Novo Liver Transplantation

Conditions

de Novo Liver Transplantation

Trial Timeline

Oct 1, 2007 → —

NCT ID

NCT00545259

About AEB071

AEB071 is a phase 1 stage product being developed by Novartis for de Novo Liver Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00545259. Target conditions include de Novo Liver Transplantation.

What happened to similar drugs?

9 of 16 similar drugs in de Novo Liver Transplantation were approved

Approved (9) Terminated (1) Active (6)

✅Tacrolimus targeted half-dose + Tacrolimus targeted plain doseAstellas PharmaApproved

✅Prograf + AdvagrafAstellas PharmaApproved

✅ATG-FAstellas PharmaApproved

✅Advagraf + Prograf + Corticosteroid + Mycophenolate mofetilAstellas PharmaApproved

✅Tacrolimus targeted half-dose + Tacrolimus targeted plain doseAstellas PharmaApproved

✅Enteric-coated Mycophenolate sodium (EC-MPS)NovartisApproved

✅Enteric-Coated Mycophenolate Sodium (EC-MPS)NovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01430416	Phase 1	Completed	Dec 20, 2011	May 22, 2019	Uveal Melanoma
NCT01402440	Phase 1	Terminated	Nov 1, 2011	Apr 1, 2014	Diffuse Large B-Cell Lymphoma
NCT00615693	Phase 2	Completed	Jul 1, 2008	—	Uveitis
NCT00545259	Phase 1	Completed	Oct 1, 2007	—	de Novo Liver Transplantation
NCT00492869	Phase 1/2	Completed	Jan 1, 2007	—	Kidney Transplantation
NCT00416546	Phase 1	Completed	Oct 1, 2006	Oct 1, 2007	Healthy
NCT00409929	Phase 1	Completed	Jun 1, 2006	—	Healthy

Competing Products

19 competing products in de Novo Liver Transplantation

See all competitors

Product	Company	Stage	Hype Score
Alefacept + placebo + Tacrolimus + Mycophenolate Mofetil + Steroids	Astellas Pharma	Phase 2	35
Tacrolimus targeted half-dose + Tacrolimus targeted plain dose	Astellas Pharma	Approved	39
Prograf + Advagraf	Astellas Pharma	Approved	43
ATG-F	Astellas Pharma	Approved	43
Advagraf + Prograf + Corticosteroid + Mycophenolate mofetil	Astellas Pharma	Approved	43
Tacrolimus targeted half-dose + Tacrolimus targeted plain dose	Astellas Pharma	Approved	39
Venetoclax + Azacitidine + Cytarabine + Methotrexate + Hydrocortisone + Leucovorin + Dexamethasone + Vincristine + Doxorubicin + Dexrazoxane + Calaspargase Pegol + Erwinia asparaginase	AbbVie	Phase 1	36
Birabresib Dose 20 mg	Merck	Phase 1	21
Enteric-coated Mycophenolate sodium (EC-MPS)	Novartis	Phase 3	32
Enteric-coated Mycophenolate sodium (EC-MPS)	Novartis	Approved	43
Enteric-Coated Mycophenolate Sodium (EC-MPS)	Novartis	Approved	43
everolimus + cyclosporine + Prednison (continuous steroids)	Novartis	Phase 3	40
Enteric-coated Mycophenolate sodium (EC-MPS)	Novartis	Phase 3	40
Enteric-Coated Mycophenolate Sodium	Novartis	Phase 3	40
EC-MPS	Novartis	Phase 3	40
Enteric-coated Mycophenolate sodium (EC-MPS), valsartan	Novartis	Phase 3	40
everolimus	Novartis	Phase 3	40
Prograf + Tacrolimus Hexal	Novartis	Approved	43
Mycophenolate Mofetil	Roche	Approved	43